Corvus Pharmaceuticals, Inc. (CRVS) Stock Price & Analysis
Corvus Pharmaceuticals, Inc. (CRVS) closed at USD 10.23 on Thursday, October 29, 2026, down 2.76% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 10.52; the Oct 29, 2026 session ranged USD 10.18–10.74 on volume of 852,138 shares. Market capitalization is $860.56M, with a 52-week range of USD 6.39–26.95 (NGM). Source: Nexqual, retrieved October 29, 2026 at 22:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRVS.md
Key facts (CRVS)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $334K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 33.14 (range 27–42).
- Total return with dividends: 1Y +31.8% vs S&P 500 +14.4%; 5Y +125.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.21, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: CRVS paid no cash dividend in the last five years.
- Short interest: 24.28% of float (as of 2026-10-15), 13.9 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CRVS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M | -$57.0M |
| Net income | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M | -$54.1M |
| EPS (diluted) | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 | — |
| Free cash flow | -$36.7M | -$27.3M | -$24.0M | — | -$33.0M | -$45.2M |
| Cash + short-term investments | $69.5M | $42.3M | $27.1M | $52.0M | $56.8M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CRVS)
P/B 3.8x · FCF yield -5.26% · Earnings yield -6.29%
Insider purchases (SEC Form 4, open-market, last ~7 months) (CRVS)
2 purchases, $334K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-11 | Moore David Scott | Director | 21,700 | $250K | 11.53 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-18 | Miller Richard A Md | President and CEO | 6,932 | $83K | 12.04 | Too little history (no open-market trades in 2023 or 2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CRVS)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 33.14 (low 27, high 42).
Total return (dividends reinvested) (CRVS)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +31.8% | +125.8% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +32.0% | +17.6% |
| Volatility (annualized) | 118.1% | 98.3% |
| Max drawdown | -63.2% (Jan 2026→Oct 2026) | -87.0% (Nov 2021→Mar 2023) |
Dividends (CRVS)
CRVS paid no cash dividend in the last five years.
Short interest (CRVS)
17,967,756 shares sold short, 24.28% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 17,180,341 shares (+4.6%). Days to cover: 13.9 (short shares ÷ average daily volume).
CRVS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.19 | −$0.17 | Miss −11.8% | -0.1% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.15 | −$0.15 | In line | +0.6% |
| Mar 12, 2026 | Quarter ended Dec 31, 2025 | −$0.15 | −$0.13 | Miss −15.4% | -9.3% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$0.12 | −$0.13 | Beat +7.7% | -2.0% |
| Aug 7, 2025 | — | — | — | — | +3.4% |
| May 8, 2025 | — | — | — | — | +38.4% |
| Mar 25, 2025 | — | — | — | — | -21.2% |
| Nov 12, 2024 | — | — | — | — | -7.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CRVS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 7, 2026 | Schedule 13G | STATE STREET CORPORATION: 5.3% of shares, passive 5%+ holder |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Jul 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 7.5% of shares, passive 5%+ holder (amended) |
| Jul 22, 2026 | 8-K | Director or executive officer change, or pay arrangement “On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the "Board") of Corvus Pharmaceuticals, Inc. (the "Company"), effective as of July 22, 2026. The Company thanks Mr. Clark for his significant contributions to the Company during over nine years of Board service.” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CRVS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Angel Pharmaceuticals | “Under our collaboration with Angel Pharmaceuticals, Angel Pharmaceuticals is responsible for the clinical development and commercialization, including all related expenses, of the licensed pipeline programs in greater China, and for the pre-clinical BTK program globally.” |
Quoted from the company's 10-K filed Mar 12, 2026.
CRVS company outlook (results filed Aug 6, 2026)
- “The trial is anticipated to enroll approximately 200 patients with moderate-to-severe atopic dermatitis that have failed at least one prior topical or systemic therapy.”
- “Results from cohort 1 (100 mg twice per day, 200 mg once per day and placebo) are anticipated late this year.”
- “The funding is anticipated to support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial of soquelitinib for asthma.”
- “Angel Pharma anticipates that it will initiate the Phase 2 asthma trial in early 2027.”
Quoted word-for-word from the SEC 8-K results press release.
CRVS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.20 | $-0.19 | −$0.01 | $0 | 4 |
| Next quarter (ends Dec 2026) | $-0.23 | $-0.21 | −$0.02 | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-0.78 | $-0.72 | −$0.06 | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-1.07 | $-0.95 | −$0.12 | $4.5M | 4 |
CRVS options: expected move
Options price a move of about ±20.8% (±$2.17) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±10.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 103.5% | ±20.8% |
| Dec 18, 2026 | 50 | 79.0% | ±26.7% |
| Jan 15, 2027 | 78 | 96.6% | ±35.3% |
| Apr 16, 2027 | 169 | 89.5% | ±47.5% |
30-day implied volatility 78.1% vs 57.2% realized over the last 30 trading days. Put/call ratio (volume) 0.26. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 22:21 UTC)
| Price | USD 10.23 |
|---|---|
| Change | ▼ 2.76% (down) |
| Previous Close | USD 10.52 |
| Open | USD 10.57 |
| Day Range | USD 10.18 – 10.74 |
| 52-Week Range | USD 6.39 – 26.95 |
| Volume | 852,138 shares |
| Market Cap | $860.56M |
| Exchange | NGM |
Technical Analysis (CRVS)
Nexqual's technical model rates CRVS "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 22:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.13 (neutral) |
| vs SMA50 | Below (USD 12.03) |
| MACD | -0.42 (negative) |
Analyst Ratings (CRVS)
Wall Street analysts rate CRVS "Buy" based on 8 analysts, with a mean price target of USD 33.14 (range USD 27–42), per Nexqual as of October 29, 2026 at 22:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 33.14 |
| High Target | USD 42 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CRVS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.19 vs est -0.17 ▼ miss |
| 2026-03-31 | USD -0.15 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
Source: Nexqual, October 29, 2026 at 22:21 UTC.
Financials & Fundamentals (CRVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -35.43% |
| Debt / Equity | 0 |
| Current Ratio | 16.16 |
| Total Cash | $215.23M |
| Total Debt | $728,000 |
Source: Nexqual, October 29, 2026 at 22:21 UTC.
Financial Health Score (CRVS)
Nexqual rates Corvus Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 22:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $215M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$33M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -24%, ROA -22.6% (last 4 quarters, SEC) |
Ownership (CRVS)
| Insider Ownership | +3.51% |
|---|---|
| Institutional Ownership | +85.79% |
| Shares Outstanding | 84.12M |
| Float | 72.79M |
| Short % of Float | +24.28% |
Source: Nexqual, October 29, 2026 at 22:21 UTC.
Leadership (CRVS)
Corvus Pharmaceuticals, Inc. is led by Richard A. Miller, Co-Founder, President, CEO & Chairman of the Board, per Nexqual as of October 29, 2026 at 22:21 UTC.
| Co-Founder, President, CEO & Chairman of the Board | Richard A. Miller |
|---|---|
| Co-Founder & Independent Director | Peter A. Thompson FACP |
| Chief Financial Officer | Leiv Lea |
| Senior Vice President of Pharmaceutical Development | William Benton Jones |
Major Backers & Investors (CRVS)
Notable institutional backers of Corvus Pharmaceuticals, Inc. include Orbimed Advisors LLC., Price (T.Rowe) Associates Inc, Adams Street Partners, LLC, according to Nexqual as of October 29, 2026 at 22:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 8.52% |
| Price (T.Rowe) Associates Inc | 4.5% |
| Adams Street Partners, LLC | 3.89% |
| Vivo Capital, LLC | 3.34% |
| Wellington Management | 3.25% |
| Perceptive Advisors Llc | 3.17% |
| Deep Track Capital, Lp | 2.96% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.49% |
| State Street | 5.32% |
| Vanguard Group | 3.91% |
Source: Nexqual, October 29, 2026 at 22:21 UTC.
From Corvus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-oncology.
- A new drug must be approved by the FDA through the New Drug Application ("NDA") process and a new biologic must be approved by the FDA through the Biologics License Application ("BLA") process before it may be legally marketed in the United States.
- In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act ("FDCA"), and in the case of biologics, also under the Public Health Service Act ("PHSA"), and their implementing regulations.
- We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Partnerships
- Our license agreement with Scripps will terminate upon expiration of our obligation to pay royalties to Scripps under the license agreement.
- The term of our agreement with Monash continues until the expiration of our obligation to pay royalties to Monash thereunder.
Legal & Regulatory Risks (Item 1A, quoted)
- Our product candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.
- Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.
- We rely, and expect to continue to rely, on third parties to conduct our clinical trials. If these third parties do not meet our deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected, or at all.
- We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products and the contract manufacturers on which we rely may not continue to meet regulatory requirements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt